Man Group PLC Aeglea Bio Therapeutics, Inc. Transaction History

Man Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.38 - $0.81 $7,288 - $15,534	19,179 Added 125.36%	34,478 $18,000
Q2 2022 Aug 15, 2022	BUY	$0.5 - $2.66 $7,649 - $40,695	15,299 New	15,299 $8,000
Q1 2020 May 15, 2020	SELL	$3.51 - $8.48 $144,587 - $349,316	-41,193 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$6.42 - $9.0 $324,312 - $454,644	-50,516 Reduced 55.08%	41,193 $317,000
Q2 2019 Aug 14, 2019	BUY	$6.1 - $8.78 $9,760 - $14,047	1,600 Added 1.78%	91,709 $628,000
Q1 2019 May 15, 2019	SELL	$7.6 - $9.4 $260,672 - $322,410	-34,299 Reduced 27.57%	90,109 $725,000
Q4 2018 Feb 14, 2019	SELL	$6.51 - $10.19 $1.14 Million - $1.78 Million	-175,028 Reduced 58.45%	124,408 $932,000
Q3 2018 Nov 14, 2018	SELL	$8.24 - $11.0 $215,682 - $287,925	-26,175 Reduced 8.04%	299,436 $2.87 Million
Q2 2018 Aug 14, 2018	BUY	$7.87 - $10.89 $2.56 Million - $3.55 Million	325,611 New	325,611 $3.45 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.